Pressmeddelanden, rapporter och bolagsmeddelande för PILA PHARMA AB

PILA PHARMA AB has initiated a rights issue of units to raise approximately 20 million SEK, with the subscription period running from July 1 to July 15, 2025. Existing shareholders have preferential rights, and the issue includes a maximum of 9,994,019 units, each comprising one newly issued share and one warrant. The subscription price is SEK 2.00 per unit. The warrants allow holders to subscribe for additional shares between February 5 and February 15, 2026, at a price determined by the average market price, with certain limits. The company has secured commitments covering nearly the entire rights issue amount. An over-allotment issue may occur if the rights issue is oversubscribed. PILA PHARMA focuses on developing treatments for obesity, type 2 diabetes, and erythromelalgia using TRPV1 antagonists, specifically the compound XEN-D0501. The company is preparing for further clinical trials to assess safety and efficacy in treating these conditions. The press release includes legal disclaimers about distribution restrictions and forward-looking statements.

PILA PHARMA AB, a Swedish biotech company, announced a recent interview with Helge Larsen from ProInvestor, Denmark's largest online forum for investors in biotechnology and pharmaceuticals. During the interview, CEO Gustav H. Gram discussed the company's upcoming rights issue, which is nearly fully backed by investors and guarantors. The funds raised will support new obesity studies. PILA PHARMA focuses on developing TRPV1 antagonists, particularly XEN-D0501, for treating type 2 diabetes, obesity, erythromelalgia, and abdominal aorta aneurysm. XEN-D0501 has shown promise in clinical trials for diabetes and obesity, and research continues into its efficacy for other conditions. The company is preparing for further clinical trials and exploring potential treatments for obesity and related diseases.

PILA PHARMA AB announced that June 25, 2025, is the last day for trading shares that include rights to receive unit rights related to a rights issue resolved by the Board on June 19, 2025. Shareholders registered by June 27, 2025, will receive one unit right per share, with 19 unit rights allowing subscription for seven units. Each unit includes one new share and one warrant of series TO2, priced at SEK 2.00 per unit. The warrants, issued free of charge, allow holders to subscribe for two new shares between February 5-15, 2026, at a price determined by the average market price prior to February 5, 2026, but not less than SEK 1.50 or more than SEK 3.00 per share. The subscription period for the rights issue is from July 1-15, 2025, with existing shareholders and management committing approximately SEK 10.22 million, and additional guarantee commitments of SEK 9.75 million, covering nearly 99.87% of the issue. If oversubscribed, an over-allotment issue may be conducted. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 antagonists for obesity and type 2 diabetes treatment, with its candidate XEN-D0501 showing promising results in clinical trials. The company is also exploring treatments for erythromelalgia and abdominal aorta aneurism. Legal and issuing advisors for the rights issue are MAQS Advokatbyrå and Nordic Issuing, respectively.

PILA PHARMA AB announced a rights issue of units, involving new shares and warrants, valued at approximately SEK 20 million. The Swedish Financial Supervisory Authority has approved the prospectus related to this issue. Shareholders as of June 27, 2025, will receive unit rights, allowing them to subscribe for new units at SEK 2.00 each. The subscription period is from July 1 to July 15, 2025. The company aims to use the proceeds primarily for preclinical trials of its drug candidate XEN-D0501 for obesity and for working capital. PILA PHARMA is a Swedish biotech firm focused on developing treatments for obesity and type 2 diabetes using TRPV1 antagonists. The company has completed phase 2a trials for XEN-D0501, showing positive results in enhancing insulin response and reducing heart failure biomarkers. The drug is also being explored for other conditions like erythromelalgia and abdominal aorta aneurism. The press release emphasizes that it is not an offer or solicitation for securities in jurisdictions where such actions would be unlawful.

PILA PHARMA AB's Board of Directors has announced a Rights Issue to raise approximately SEK 20 million by issuing new shares and warrants. The subscription price is set at SEK 2 per unit. Shareholders registered by June 27, 2025, will receive unit rights, allowing them to subscribe to new shares and warrants. The Rights Issue is supported by commitments from existing shareholders and management, covering about 99.87% of the total amount. If fully subscribed, the company will net approximately SEK 18 million after transaction costs. An Over-allotment Issue may be conducted if the Rights Issue is oversubscribed, potentially raising an additional SEK 9.9 million. The funds will primarily support the development of the company's drug candidate, XEN-D0501, targeting obesity and type 2 diabetes. The subscription period is from July 1 to July 15, 2025. The complete terms will be detailed in a prospectus expected to be published on June 25, 2025. PILA PHARMA is a Swedish biotech firm focused on developing treatments for obesity and diabetes, with interests in other diseases such as erythromelalgia and abdominal aortic aneurysm.

PILA PHARMA AB (publ) is a Swedish biotech company focused on developing TRPV1 antagonists as novel treatments for type 2 diabetes, obesity, and other inflammatory diseases. The company recently shared recordings of presentations by CEO Gustav H. Gram, discussing their lead candidate, XEN-D0501, and its potential in treating obesity and diabetes. XEN-D0501 has shown promise in clinical trials, demonstrating good tolerability and efficacy in enhancing insulin response and reducing cardiovascular biomarkers. The company is preparing for further trials to explore its maximal tolerable dose and efficacy in weight reduction. PILA PHARMA also explores the use of XEN-D0501 for erythromelalgia and abdominal aorta aneurysm, with ongoing research collaborations and plans for proof-of-concept studies. The company aims to address the growing global challenges of obesity and diabetes, which are linked to significant health risks and economic burdens.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs targeting the TRPV1 receptor for obesity and diabetes treatment. The company recently participated in an online investment presentation, discussing its approach and the industry's shift towards oral treatment solutions. PILA PHARMA's lead candidate, XEN-D0501, is a TRPV1 antagonist shown to be effective and well-tolerated in early clinical trials for obesity and type 2 diabetes. The company is preparing for further trials to assess the drug's safety and efficacy. Additionally, PILA PHARMA is exploring the use of XEN-D0501 for treating erythromelalgia and abdominal aorta aneurysm, with promising preclinical results. The company holds patents for TRPV1 antagonists and continues to advance its research and development efforts in these areas.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs based on TRPV1 inhibition for treating obesity and diabetes. CEO Gustav H. Gram discussed the company's goals and the broader market trends, including the 'Longevity' movement, on the 10X podcast. The podcast is available in English, with the PILA segment starting at 33:10. PILA PHARMA is focused on developing TRPV1 antagonists, specifically XEN-D0501, for treating type 2 diabetes and other inflammatory diseases. The company has completed successful phase 2a trials and is preparing for further clinical trials, aiming to identify the maximal tolerable dose and evaluate the safety of XEN-D0501 in people with obesity and type 2 diabetes. The company is also exploring treatments for erythromelalgia and abdominal aorta aneurysm, with promising preclinical results for XEN-D0501 in reducing aneurysm growth in mice. PILA PHARMA's projects are available for out-licensing, and the company continues to advance its research and development efforts.

PILA PHARMA AB, a Swedish biotech company focused on developing novel oral drugs for obesity and diabetes using TRPV1 inhibition, is hosting an after-work event on June 11 in Stockholm. The event will feature updates from CEO Gustav H. Gram and Founder Dorte X. Gram on the company's progress and plans, as well as a Q&A session. PILA PHARMA is advancing its development candidate XEN-D0501, a TRPV1 antagonist, which has shown promise in clinical trials for obesity and type 2 diabetes. The company is also exploring its potential for treating erythromelalgia and abdominal aorta aneurysm. PILA PHARMA's shares are traded on Nasdaq First North Growth Market.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs based on TRPV1 inhibition for treating obesity and diabetes. The company invites investors to several upcoming events where CEO Gustav H. Gram will discuss the company's innovative treatments and market outlook. PILA PHARMA focuses on developing TRPV1 antagonists like XEN-D0501, which have shown potential in treating metabolic disorders. The company has completed two phase 2a trials demonstrating XEN-D0501's safety and efficacy in enhancing insulin response and reducing cardiovascular biomarkers. PILA PHARMA is preparing for a new clinical trial to assess the maximal tolerable dose of XEN-D0501 for obesity and type 2 diabetes. The company also explores treatments for erythromelalgia and abdominal aorta aneurysm, with promising preclinical results for the latter. PILA PHARMA's shares are traded on Nasdaq First North Growth Market, Sweden.